At a glance
ClinicalIndex Comparison RecordPhase 1Unknown· 48 target
Drug / intervention
BAT8009 for Injectiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT8009 in Patients With Advanced Solid Tumours
In Brief
A Phase 1 clinical trial evaluating BAT8009 for Injection for Locally Advanced/Metastatic Solid Tumours. Targeting 48 participants across 1 site.
Detailed Summary
Primary objectives: * To evaluate the safety and tolerability of BAT8009 in patients with advanced solid tumours. * To determine the maximum tolerated dose (MTD) and recommended dose for Phase 2 (RP2D).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--
Timeline
Phase 1UnknownOverdue
2023202420252026
First PostedJun 2022
Enrollment StartAug 2022
Primary CompletionDec 2023
Study CompletionDec 2024
TodayJul 2026
First PostedJun 6, 2022
Enrollment StartAug 2, 2022
Primary CompletionDec 1, 2023
Study CompletionDec 1, 2024
TodayJul 1, 2026
Enrollment to primary: 1.3 yearsPosted 4.1 years ago
Interventions
BAT8009 for Injectiondrug
BAT8009 will be administered as a 90-minute (± 5min) IV infusion on Day 1 of Cycle 1. If there is no infusion related reaction after initial dose, the next dose of BAT8009 will be infused intravenously into each patient for approximately 30\~120 minutes.